BioLargo Q2 2022 revenue ~$1.3M, up 185% YoY; preliminary figures

BIOLARGO, INC.

Q2 revenue ~$1.3M, up 37% sequentially and 185% vs Q2 2021.
Growth driven by POOPH retail launch, PFAS treatment tech, waste-to-energy project.
National nuclear fuel innovator prototype project expected to expand after successful Phase 1.
Full Q2 results due in Form 10-Q by Aug 15, 2022; figures preliminary and unaudited.
Company plans investor webcast shortly after 10-Q filing.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.